Alejandra Sanjuan Pla

She obtained her Ph.D. in Pharmacy at Universitat de València (2002). Then, she continued her career as postdoctoral researcher in the hematopoietic field working at different European institutions and mainly studying the heterogeneity of murine hematopoietic stem cells (HSC) and platelet-biased HSC. After that, she worked on infant acute lymphoblastic leukemia with MLL rearrangements at Josep Carreras Leukemia Research Institute in Barcelona. Since 2017, she is a Ramón y Cajal researcher at IIS La Fe. Here, she studies the functional role of some mutations found in myelodysplastic syndromes and acute myeloid leukemia patients using in vitro and in vivo models.

Research line: In vivo modeling of myelodysplastic syndromes

1. CRISPR/Cas9 modeling for studying the impact of (epi)genetic co-occurrent mutations in myelodysplastic syndromes (SAF-2017-82171)

To functionally characterize hematopoietic cells with alterations in splicing factors by in vitro and in vivo assays
To molecular characterize hematopoietic cells with alterations in splicing factors by RNA sequencing
To study the cooperation between splicing and epigenetic mutations in the pathogenesis of myelodysplastic syndromes

2. Developing new models for myelodysplastic syndromes (Beca Leonardo a investigadores y creadores culturales, Fundación BBVA).

To optimize gene editing using CRISPR/Cas technology in hematopoietic primary cells.